The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Journavx targets specific proteins in the body called sodium channels. Sodium channels help send pain signals to your brain. Your brain then processes how you will experience and respond to the pain.

Journavx has been specifically approved for the treatment of moderate-to-severe acute pain, which often results from injury, surgery, illness, trauma or painful medical procedures, ...

Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 years. [READ: Understanding the Impact of Health Conditions and Medications on Seniors] ...

Journavx showed a “statistically significant superior reduction in pain” when compared to a placebo in two randomized trials of acute surgical pain, according to the FDA.

Significantly, Journavx didn’t provide better pain relief than the opioid combination in one of the trials and was inferior to the combination in the other trial.

But Journavx has its limitations, experts said, as the drug is not approved yet for chronic pain and at $15.50 per pill is more expensive than most opioids. Adam Birkenstock, ...

Alyftrek and Journavx — The Two Big Launches. According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyftrek and Journavx.

Journavx was found to help reduce pain by blocking pain signals in the peripheral nervous system before pain signals reach the brain. Reshma Kewalramani, CEO and president of Vertex, ...

A new drug - Journavx - has been approved by the FDA for severe pain, such as that which can follow surgical procedures. A woman recovering from knee surgery and undergoing a scan.

Journavx has been specifically approved for the treatment of moderate-to-severe acute pain, which often results from injury, surgery, illness, trauma or painful medical procedures, ...

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years.